Elsevier

Biological Psychiatry

Volume 80, Issue 12, 15 December 2016, Pages 916-922
Biological Psychiatry

Archival Report
Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Depression: A Nationwide Longitudinal Cohort Study

https://doi.org/10.1016/j.biopsych.2016.02.018Get rights and content

Abstract

Background

Attention-deficit/hyperactivity disorder (ADHD) is associated with high rates of psychiatric comorbidity, including depression. However, it is unclear whether ADHD medication increases or decreases the risk for depression.

Methods

We studied all individuals with a diagnosis of ADHD born between 1960 and 1998 in Sweden (N = 38,752). We obtained data for prescription of ADHD medication, diagnosis of depression and other psychiatric disorders, and sociodemographic factors from population-based registers. The association between ADHD medication and depression was estimated with Cox proportional hazards regression.

Results

After adjustment for sociodemographic and clinical confounders, ADHD medication was associated with a reduced long-term risk (i.e., 3 years later) for depression (hazard ratio = 0.58; 95% confidence interval, 0.51–0.67). The risk was lower for longer duration of ADHD medication. Also, ADHD medication was associated with reduced rates of concurrent depression; within-individual analysis suggested that occurrence of depression was 20% less common during periods when patients received ADHD medication compared with periods when they did not (hazard ratio = 0.80; 95% confidence interval, 0.70–0.92).

Conclusions

Our study suggests that ADHD medication does not increase the risk of later depression; rather, medication was associated with a reduced risk for subsequent and concurrent depression.

Section snippets

Study Population

We used data from several population-based registers in Sweden, which were linked with unique personal identification numbers (22). The study participants were identified from the National Patient Register, which has nationwide coverage of information on psychiatric inpatient care since 1973 and outpatient visits to specialists (not general practitioners) since 2001. We identified 38,752 patients with a clinical diagnosis of ADHD (ICD-10 code F90) who were born between 1960 and 1998 and were

Results

Table 1 lists the descriptive statistics for all patients included in this study. We identified 38,752 patients with ADHD, of whom 2987 experienced depression events in 2009. Among male patients, 16.8% received ADHD medication on January 1, 2006, and 51.3% received ADHD medication at least once during the period between January 1, 2006, and December 31, 2008, with median length of treatment of 1.2 years (interquartile range, 0.5–2.4 years). Corresponding figures in female patients were 10.9%,

Discussion

In this large, population-based cohort study, we followed 38,752 patients with ADHD for 4 years to investigate the association between ADHD medication and depression. The results suggested that ADHD medication was associated with a reduced long-term risk of depression after adjustment for sociodemographic and clinical confounders. The risk was lower for longer duration of ADHD medication. In addition, ADHD medication was associated with reduced rates of concurrent depression, even when using

Acknowledgments And Disclosures

This work was supported by the Swedish Research Council Grant No. 2013-2280, Swedish Initiative for Research on Microdata in the Social And Medical Sciences framework Grant No. 340-2013-5867, National Institute of Mental Health Grant No. 1R01MH102221, Swedish Research Council for Health, Working Life and Welfare Grant No. 2014-2780 (to ZC), and Indiana Clinical and Translational Sciences Institute Grant No. TL1 TR001107 (to PDQ). The funders had no role in study design, data collection and

References (37)

  • S.V. Faraone et al.

    The worldwide prevalence of ADHD: Is it an American condition?

    World Psychiatry

    (2003)
  • S.R. Pliszka

    Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: An overview

    J Clin Psychiatry

    (1998)
  • A. Angold et al.

    Comorbidity

    J Child Psychol Psychiatry

    (1999)
  • R.A. Barkley

    Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder

    J Clin Psychiatry

    (2002)
  • W.B. Daviss

    A review of co-morbid depression in pediatric ADHD: Etiology, phenomenology, and treatment

    J Child Adolesc Psychopharmacol

    (2008)
  • W.B. Daviss et al.

    Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression?

    J Child Adolesc Psychopharmacol

    (2008)
  • J. Waxmonsky

    Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness

    Curr Opin Pediatr

    (2003)
  • V. Chirdkiatgumchai et al.

    National trends in psychotropic medication use in young children: 1994-2009

    Pediatrics

    (2013)
  • Cited by (82)

    View all citing articles on Scopus
    View full text